ReviewIranian journal of basic medical sciences2026
Resveratrol as an immune checkpoint inhibitor to enhance the efficacy of breast cancer immunotherapy.
Review in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major goal in cancer treatment is to convert "cold" tumors into "hot" ones by altering the tumor microenvironment (TME). Breast cancer is often a cold tumor and is resistant to immunotherapy. Resveratrol is a polyphenolic compound found in grapes, with antioxidant, anti-inflammatory, and potential cardioprotective and anti-aging properties. Resveratrol promotes the conversion of immunologically cold breast tumors into hot tumors, thereby increasing the efficacy of immunotherapy. This article reviews the potential of resveratrol to convert immunologically "cold" breast tumors into "hot" tumors by modulating the TME and enhancing the efficacy of immunotherapy. A comprehensive literature search was conducted in PubMed, Scopus, Web of Science, and Google Scholar to identify English-language articles investigating the effects of resveratrol on immune checkpoints in breast cancer. The results showed that resveratrol suppresses key cancer-promoting pathways (PI3K/Akt/mTOR, MAPK/ERK, STAT/NF-κB, and Wnt/β-catenin) and modulates the immune system. It boosts anti-tumor immunity by activating immunostimulatory cells (such as M1-TAMs, NKs, and CTLs) while simultaneously inhibiting immunosuppressive cells (such as Tregs and MDSCs). It also acts as a natural immune checkpoint inhibitor by targeting the PD-1/PD-L1 pathway. Resveratrol prevents T-cell exhaustion in "cold" tumors and reduces PD-L1 expression in "hot" tumors, thereby enhancing cytotoxic T cells' ability to attack cancer. However, its effectiveness is limited by poor bioavailability and differences in the biological activity of its metabolites. Future clinical studies are needed to confirm these results and determine optimal therapeutic protocols for resveratrol-mediated breast cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.